Clinical Trial Update: Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT [Phase 1]

View source ↗

Summary

This clinical trial update describes a Phase 1 study evaluating donor-derived anti-CD123 CAR T cells for relapse of acute myeloid leukemia after allogeneic hema…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Anti-CD123-CART Cells (donor-derived anti-CD123 CAR T cells)

Snippet

Sponsor: Affiliated Hospital to Academy of Military Medical Sciences | Conditions: Adult Acute Myeloid Leukemia | Phase 1 | Status: UNKNOWN